72 related articles for article (PubMed ID: 7700213)
1. Discriminants of prevalent fractures in chronic kidney disease.
Nickolas TL; Cremers S; Zhang A; Thomas V; Stein E; Cohen A; Chauncey R; Nikkel L; Yin MT; Liu XS; Boutroy S; Staron RB; Leonard MB; McMahon DJ; Dworakowski E; Shane E
J Am Soc Nephrol; 2011 Aug; 22(8):1560-72. PubMed ID: 21784896
[TBL] [Abstract][Full Text] [Related]
2. Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder.
Peters BS; Moyses RM; Jorgetti V; Martini LA
Int Urol Nephrol; 2007; 39(4):1251-6. PubMed ID: 17680337
[TBL] [Abstract][Full Text] [Related]
3. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
Katagiri M; Fukunaga M; Ohtawa T; Harada T
World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
[TBL] [Abstract][Full Text] [Related]
4. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
5. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
[TBL] [Abstract][Full Text] [Related]
6. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure.
Franke S; Lehmann G; Abendroth K; Hein G; Stein G
Eur J Med Res; 1998 Feb; 3(1-2):81-8. PubMed ID: 9512973
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases.
Santi I; Monti M; Viganò A; D'Aprile E; Rampoldi E; Castellani L; Accinni R; Cunietti E
Int J Biol Markers; 1995; 10(2):107-12. PubMed ID: 7561234
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
9. Circulating biochemical markers of bone remodeling in uremic patients.
Ureña P; De Vernejoul MC
Kidney Int; 1999 Jun; 55(6):2141-56. PubMed ID: 10354264
[TBL] [Abstract][Full Text] [Related]
10. Biological markers in the diagnosis of the different forms of renal osteodystrophy.
Ferreira A; Drüeke TB
Am J Med Sci; 2000 Aug; 320(2):85-9. PubMed ID: 10981481
[TBL] [Abstract][Full Text] [Related]
11. [Clinical usefulness of bone turnover markers with the treatment of osteoporosis].
Miura M
Clin Calcium; 2014 Mar; 24(3):367-76. PubMed ID: 24576933
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers of bone turnover: an update.
van Daele PL; Birkenhäger JC; Pols HA
Neth J Med; 1994 Feb; 44(2):65-72. PubMed ID: 8208326
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
